{"title":"Correction to Lancet Oncol 2025; 26: 367–77","authors":"","doi":"10.1016/s1470-2045(25)00144-5","DOIUrl":null,"url":null,"abstract":"<em>Zdenkowski N, Kuper-Hommel MJJ, Niman SM, et al. Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.</em> Lancet Oncol <em>2025; <strong>26:</strong> 367–77</em>—The appendix of this Article has been corrected as of March 31, 2025.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"33 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(25)00144-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Zdenkowski N, Kuper-Hommel MJJ, Niman SM, et al. Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial. Lancet Oncol 2025; 26: 367–77—The appendix of this Article has been corrected as of March 31, 2025.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
